BN Business News
Add your company to Business Communicator →

Business · 09/12/2021Updated: 10/17/2026 · 1 min read

Fresenius Kabi Deutschland GmbH Seeks Withdrawal of FDA Approval for VOLUVEN

Summary

The FDA is withdrawing approval of a new drug application for VOLUVEN, a 6% hydroxyethyl starch solution, due to Fresenius Kabi Deutschland GmbH's request, as the drug is no longer commercially available.

Original source language: Federal Register — Food and Drug AdministrationOpen original release →

Explore insights

Business insights →